Open label trial of coenzyme Q10 as a migraine preventive

Todd Rozen, M. L. Oshinsky, C. A. Gebeline, K. C. Bradley, W. B. Young, A. L. Shechter, S. D. Silberstein

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

The objective was to assess the efficacy of coenzyme Q10 as a preventive treatment for migraine headaches. Thirty-two patients (26 women, 6 men) with a history of episodic migraine with or without aura were treated with coenzyme Q10 at a dose of 150 mg per day. Thirty-one of 32 patients completed the study; 61.3% of patients had a greater than 50% reduction in number of days with migraine headache. The average number of days with migraine during the baseline period was 7.34 and this decreased to 2.95 after 3 months of therapy, which was a statistically significant response (P < 0.0001). Mean reduction in migraine frequency after 1 month of treatment was 13.1% and this increased to 55.3% by the end of 3 months. Mean migraine attack frequency was 4.85 during the baseline period and this decreased to 2.81 attacks by the end of the study period, which was a statistically significant response (P < 0.001). There were no side-effects noted with coenzyme Q10. From this open label investigation coenzyme Q10 appears to be a good migraine preventive. Placebo-controlled trials are now necessary to determine the true efficacy of coenzyme Q10 in migraine prevention.

Original languageEnglish (US)
Pages (from-to)137-141
Number of pages5
JournalCephalalgia
Volume22
Issue number2
DOIs
StatePublished - May 20 2002
Externally publishedYes

Fingerprint

coenzyme Q10
Migraine Disorders
Migraine without Aura
Migraine with Aura

Keywords

  • Coenzyme Q10
  • Migraine
  • Mitochondria

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Rozen, T., Oshinsky, M. L., Gebeline, C. A., Bradley, K. C., Young, W. B., Shechter, A. L., & Silberstein, S. D. (2002). Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia, 22(2), 137-141. https://doi.org/10.1046/j.1468-2982.2002.00335.x

Open label trial of coenzyme Q10 as a migraine preventive. / Rozen, Todd; Oshinsky, M. L.; Gebeline, C. A.; Bradley, K. C.; Young, W. B.; Shechter, A. L.; Silberstein, S. D.

In: Cephalalgia, Vol. 22, No. 2, 20.05.2002, p. 137-141.

Research output: Contribution to journalArticle

Rozen, T, Oshinsky, ML, Gebeline, CA, Bradley, KC, Young, WB, Shechter, AL & Silberstein, SD 2002, 'Open label trial of coenzyme Q10 as a migraine preventive', Cephalalgia, vol. 22, no. 2, pp. 137-141. https://doi.org/10.1046/j.1468-2982.2002.00335.x
Rozen T, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002 May 20;22(2):137-141. https://doi.org/10.1046/j.1468-2982.2002.00335.x
Rozen, Todd ; Oshinsky, M. L. ; Gebeline, C. A. ; Bradley, K. C. ; Young, W. B. ; Shechter, A. L. ; Silberstein, S. D. / Open label trial of coenzyme Q10 as a migraine preventive. In: Cephalalgia. 2002 ; Vol. 22, No. 2. pp. 137-141.
@article{23a971c095b44b9da7a7914a3dde1e9d,
title = "Open label trial of coenzyme Q10 as a migraine preventive",
abstract = "The objective was to assess the efficacy of coenzyme Q10 as a preventive treatment for migraine headaches. Thirty-two patients (26 women, 6 men) with a history of episodic migraine with or without aura were treated with coenzyme Q10 at a dose of 150 mg per day. Thirty-one of 32 patients completed the study; 61.3{\%} of patients had a greater than 50{\%} reduction in number of days with migraine headache. The average number of days with migraine during the baseline period was 7.34 and this decreased to 2.95 after 3 months of therapy, which was a statistically significant response (P < 0.0001). Mean reduction in migraine frequency after 1 month of treatment was 13.1{\%} and this increased to 55.3{\%} by the end of 3 months. Mean migraine attack frequency was 4.85 during the baseline period and this decreased to 2.81 attacks by the end of the study period, which was a statistically significant response (P < 0.001). There were no side-effects noted with coenzyme Q10. From this open label investigation coenzyme Q10 appears to be a good migraine preventive. Placebo-controlled trials are now necessary to determine the true efficacy of coenzyme Q10 in migraine prevention.",
keywords = "Coenzyme Q10, Migraine, Mitochondria",
author = "Todd Rozen and Oshinsky, {M. L.} and Gebeline, {C. A.} and Bradley, {K. C.} and Young, {W. B.} and Shechter, {A. L.} and Silberstein, {S. D.}",
year = "2002",
month = "5",
day = "20",
doi = "10.1046/j.1468-2982.2002.00335.x",
language = "English (US)",
volume = "22",
pages = "137--141",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Open label trial of coenzyme Q10 as a migraine preventive

AU - Rozen, Todd

AU - Oshinsky, M. L.

AU - Gebeline, C. A.

AU - Bradley, K. C.

AU - Young, W. B.

AU - Shechter, A. L.

AU - Silberstein, S. D.

PY - 2002/5/20

Y1 - 2002/5/20

N2 - The objective was to assess the efficacy of coenzyme Q10 as a preventive treatment for migraine headaches. Thirty-two patients (26 women, 6 men) with a history of episodic migraine with or without aura were treated with coenzyme Q10 at a dose of 150 mg per day. Thirty-one of 32 patients completed the study; 61.3% of patients had a greater than 50% reduction in number of days with migraine headache. The average number of days with migraine during the baseline period was 7.34 and this decreased to 2.95 after 3 months of therapy, which was a statistically significant response (P < 0.0001). Mean reduction in migraine frequency after 1 month of treatment was 13.1% and this increased to 55.3% by the end of 3 months. Mean migraine attack frequency was 4.85 during the baseline period and this decreased to 2.81 attacks by the end of the study period, which was a statistically significant response (P < 0.001). There were no side-effects noted with coenzyme Q10. From this open label investigation coenzyme Q10 appears to be a good migraine preventive. Placebo-controlled trials are now necessary to determine the true efficacy of coenzyme Q10 in migraine prevention.

AB - The objective was to assess the efficacy of coenzyme Q10 as a preventive treatment for migraine headaches. Thirty-two patients (26 women, 6 men) with a history of episodic migraine with or without aura were treated with coenzyme Q10 at a dose of 150 mg per day. Thirty-one of 32 patients completed the study; 61.3% of patients had a greater than 50% reduction in number of days with migraine headache. The average number of days with migraine during the baseline period was 7.34 and this decreased to 2.95 after 3 months of therapy, which was a statistically significant response (P < 0.0001). Mean reduction in migraine frequency after 1 month of treatment was 13.1% and this increased to 55.3% by the end of 3 months. Mean migraine attack frequency was 4.85 during the baseline period and this decreased to 2.81 attacks by the end of the study period, which was a statistically significant response (P < 0.001). There were no side-effects noted with coenzyme Q10. From this open label investigation coenzyme Q10 appears to be a good migraine preventive. Placebo-controlled trials are now necessary to determine the true efficacy of coenzyme Q10 in migraine prevention.

KW - Coenzyme Q10

KW - Migraine

KW - Mitochondria

UR - http://www.scopus.com/inward/record.url?scp=0036264542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036264542&partnerID=8YFLogxK

U2 - 10.1046/j.1468-2982.2002.00335.x

DO - 10.1046/j.1468-2982.2002.00335.x

M3 - Article

C2 - 11972582

AN - SCOPUS:0036264542

VL - 22

SP - 137

EP - 141

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 2

ER -